彤程新材料集团股份有限公司Red Avenue New Materials Group Co., Ltd.09607.HK
与关联方进行商品销售交易
Our Directors are of the view that such related party transactions were conducted on an arm’s-length basis and normal commercial terms in our ordinary and usual course of business, and that they did not distort our results of operations during the Track Record Period or render our historical results not reflective of our future performance.
During the Track Record Period, our purchases from Jingxin Holding, one of our Controlling Shareholders, amounted to RMB68.1 million, RMB86.0 million, RMB85.0 million and RMB31.4 million, respectively, representing 3.5%, 3.9%, 4.5% and 3.2% of our total purchases for the respective periods.
Business · 第 142 页
During the Track Record Period, our Company sold products (including APIs) to entities held by the controlling shareholders. We also procured from entities held by the controlling shareholders (i) products (including packaging materials and daily chemicals) and (ii) services (including property cleaning services).
Financial Information · 第 239 页
Our Directors are of the view that our related party transactions during the Track Record Period were conducted in the ordinary course of business on an arm's length basis with reference to normal commercial terms, and did not distort our track record results or render our historical results not reflective of our future performance.
广东微电新能源股份有限公司Guangdong Mic-Power New Energy Co., Ltd.
向非执行董事家族关联企业立讯精密销售
The Company confirms that the transactions with Luxshare Precision were conducted in the ordinary and usual course of business and on normal commercial terms.
Business · 第 180 页
Luxshare Precision does not constitute a majority-controlled company held by Mr. Yi Lei’s family member(s) under Rule 14A.12(2)(a), nor does it constitute a majority-controlled company held by his family member(s) and/or relative(s) under Rule 14A.21(1)(b).
During the Track Record Period, we had entered into a number of transactions with the Retained Zhen Ding Group, which (except for those set out in the ‘‘Connected Transactions’’) we expect to cease prior to the [REDACTED].
Summary · 第 10 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted in the ordinary and usual course of business and on an arm’s length basis, and they did not distinct our results of operations or make our historical results not reflective of our future performance.
Financial Information · 第 239 页
In addition, we repaid our loans from our related parties in an aggregate amount of RMB1,407.8 million on June 12, 2026.
We have entered into a number of fully exempt, partially exempt and non-exempt continuing connected transactions with Anton Oilfield Group, including: (i) Lease Procurement Framework Agreement, (ii) Leasing Service Framework Agreement, and (iii) Inspection Service Framework Agreement.
Summary · 第 7 页
During the Track Record Period, the credit period we granted to Anton Oilfield Group was relatively longer than that we granted to our other major customers.
Business · 第 123 页
Our Directors are of the view that the related party transactions were conducted in the ordinary course of business on an arm's length basis and on normal commercial terms.
We have entered into and expect to continue to conduct certain transaction after the [REDACTED] with our Controlling Shareholders and their respective associates, which will constitute non-exempt continuing connected transactions under Chapter 14A of Listing Rules.
Summary · 第 13 页
During the Track Record Period and up to the Latest Practicable Date, Huiyin Financial Leasing Co. Ltd. is a Connected Person with whom we enter into finance lease arrangements on mutually agreed terms following arm’s-length negotiations.
Business · 第 146 页
Our amounts due from related parties were non-trade in nature.
During the Track Record Period, we entered into a number of related party transactions concerning Wuzhou Xinhua and Shengzhou Xinhua controlled by the immediate family member of Mr. Zhang, which involves miscellaneous purchases and sales of goods and rendering of services.
Financial Information · 第 245 页
We also entered into a four-year lease contract in respect of certain leasehold properties from Shengzhou Xinhua as office and manufacturing premise in 2022.
Financial Information · 第 245 页
Our Directors are of the view that our related party transactions during the Track Record Period were conducted in the ordinary course of business at arm's length with reference to normal commercial terms, and would not distort our track record results or make our historical results not reflective of our future performance.
During the Track Record Period, we engaged (i) certain subsidiaries of CSPC Holdings Company Limited (石藥控股集團有限公司) (“CHL”) in China, and (ii) certain subsidiaries of CSPC Pharmaceutical in the United States, Germany and Spain as our distributors in operating our biopharmaceutical or nutritional products businesses.
Business · 第 163 页
In 2023, 2024, and 2025, our revenue generated from certain subsidiaries of CHL was RMB45.1 million, RMB23.7 million, and RMB33.8 million, respectively, and our revenue generated from certain subsidiaries of CSPC Pharmaceutical in the United States, Germany and Spain was an aggregate of RMB2.2 million, nil, and RMB1.3 million, respectively.
Business · 第 163 页
Our Directors are of the view that each of these related party transactions set out therein was conducted in the ordinary course of business on an arm’s length basis and with normal commercial terms between the relevant parties.
Our prepayments to related parties consisted of (i) prepayments for property, plant and equipment from Yantai Dongcheng Heju Pharmaceutical Technology Co., Ltd. (“Dongcheng Heju”) (煙臺東誠核聚醫藥科技有限公司), and (ii) prepayments for research and development services, representing prepaid service fees to certain CROs which are our related parties, including MITRO Clinical Medical Research Limited (“MITRO Clinical”) (南京米度臨床醫學研究有限公司), Nanning MITRO Pharmaceutical Technology Co., Ltd. (“Nanning MITRO”) (南寧米度醫藥科技有限公司), and MITRO Biotech Co. Ltd. (“MITRO Biotech”) (米度(南京)生物技術有限公司).
Financial Information · 第 268 页
As of April 30, 2026, RMB18.7 million, or 51.5%, of our amounts due to related parties as of December 31, 2025 had been subsequently settled.
Financial Information · 第 272 页
Our Directors confirm that each of the significant related party transactions during the Track Record Period was conducted on an arm’s length basis, and would not distort our results of operations over the Track Record Period or make our historical results not reflective of our future performance.
During the Track Record Period, we entered into certain trade nature transactions with our related parties, including purchases of goods and services from related parties amounting to RMB35.7 million, RMB46.0 million and RMB37.1 million in 2023, 2024 and 2025, respectively, primarily comprising property management services and other services from entities controlled by Mr. Zheng Jianjiang.
Financial Information · 第 226 页
We also acquired certain rehabilitation hospitals from related parties during the Track Record Period.
Financial Information · 第 226 页
Such amounts primarily represented investment payment due to a number of equity investment partnerships controlled by an associate of our Group and other related parties for the purpose of acquiring certain hospitals.
During the Track Record Period, we entered into certain related party transactions from time to time, primarily related to sales of NEV domain-controlled electric drive solutions and NEV domain-controlled electric drive solution components and purchase of NEV domain-controlled electric drive solution components.
Financial Information · 第 215 页
During the Track Record Period, we have sold our NEV domain-controlled electric drive solutions and NEV domain-controlled electric drive solution components to Geely Related Group, who is a related party to our Group.
Financial Information · 第 215 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted in the ordinary and usual course of business and on an arm’s length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
Our Company has entered into certain continuing connected transactions with our Controlling Shareholders and/or their respective associates.
Summary · 第 12 页
Our Directors are of the view that each of the related party transactions set out in Note 46 to the Accountants’ Report in Appendix I to this Document was conducted in the ordinary course of business on an arm’s-length basis and with normal commercial terms between the relevant parties.
Financial Information · 第 243 页
Our Directors are also of the view that our related party transactions during the Track Record Period would not distort our track record results or make our historical results not reflective of our future performance.
As of December 31, 2023 and 2024, the amounts due to related parties primarily represented the amounts due to Bosch.
Financial Information · 第 248 页
In addition, we accelerated the settlement of our amounts due to Bosch in 2025.
Financial Information · 第 249 页
In addition, as of December 31, 2025, RMB949.9 million of our bank borrowings were guaranteed by Mr. Yang, and we expect to settle such amounts before Listing.
We have entered into certain transactions with associates of Mr. Wong and Ms. Wong in the ordinary and usual course of business which, upon [REDACTED], will constitute continuing connected transactions of our Company under the Listing Rules.
Summary · 第 11 页
Our Directors are of the view that each of the related party transactions set out in Note 29 to the Accountants’ Report included in Appendix I to this document was conducted in the ordinary course of business on an arm’s length basis and with normal commercial terms between the relevant parties.
Our transactions during the Track Record Period with our related parties primarily comprised trade-related transactions of (i) purchase of products from M&G Corporation, (ii) sale of goods to our related parties, and (iii) leasing transactions with our related parties.
Financial Information · 第 188 页
All of our balances with related parties that were non-trade in nature will be fully settled prior to the [REDACTED].
Financial Information · 第 188 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm’s length basis and they did not distort our results of operations or make our historical results not reflective of our future performance.
During the Track Record Period, we entered into a number of related party transactions, including (i) purchases of intangible assets and content assets from fellow subsidiaries; (ii) purchases related to cost of sales and services from our immediate and intermediate holding companies, fellow subsidiaries and related parties which represent associates of the ultimate holding company; and (iii) sales to our immediate and intermediate holding companies, fellow subsidiaries and related parties which represent associates of the ultimate holding company.
Financial Information · 第 226 页
Our Directors believe that the related party transactions described above were carried out on an arm's length basis and will not distort our results during the Track Record Period or make such results not reflective of our future performance.
Financial Information · 第 227 页
The prepayments to fellow subsidiaries as of December 31, 2025 were primarily due to the prepayments for the broadcasting rights for the 2028 UEFA European Football Championship Euro 2028, which were made through the FTA business unit of MNC Media (as the master license holder for the MNC Group) to the license owner.
Subsequent to December 31, 2025, the Company entered into an intellectual property assignment agreement with Carraro S.p.A. on December 24, 2025 which became effective from January 1, 2026, with a total cash consideration of EUR23,271,000 (equivalent to RMB191,432,000), which was paid off in January 2026.
During the Track Record Period, our Company (i) sold medical devices, including sequencing equipment, reagents and consumables, (ii) provided research services, primarily comprising scientific research sequencing solutions and (iii) provide labor services, to our subsidiaries.
Financial Information · 第 249 页
The pricing and other principal terms of our related party transactions are determined in accordance with our internal related party transaction pricing policy.
Financial Information · 第 249 页
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm's length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
During the Track Record Period, we engaged in transactions with Supplier D for (i) the procurement of organic raw cow’s milk, (ii) the procurement of cows, and (iii) the leasing of farming facilities.
Business · 第 166 页
Such transactions formed part of a structured arrangement to resolve competitive conflicts in preparation of the [REDACTED], given that both us and Supplier D were engaged in dairy cow farming operations.
Business · 第 166 页
We have ceased all transactions with Supplier D and plan to fully settle the outstanding payable to Supplier D prior to the [REDACTED].
Procurement through supplier A aligned with industry practice and was commercially necessary to our business.
Business · 第 173 页
For the years ended December 31, 2023, 2024 and 2025, revenue generated from Supplier A amounted to RMB88.1 thousand, RMB174.1 thousand and RMB88.1 thousand, accounting for 0.01%, 0.02% and 0.01% of our total revenue, respectively;